U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07411755) titled 'A Phase 1 Study of GS101 Injection to Dupixent(R)' on Feb. 09.
Brief Summary: This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S. commercial Dupixent(R) and CN commercial Dupixent(R) in healthy adult participants in China. A total of 294 healthy male adult participants, with 98 participants per treatment group across 3 groups.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: GS101 injection
300 mg (2.0 mL)/pre-filled ...